Please assess the completion status of the following clinical trial:

Trial Title: Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females diagnosed with ongoing post-bariatric or post-gastric surgery hypoglycemia with prior episodes of neuroglycopenia~2. Age 18-65 years of age, inclusive, at screening~3. Willingness to provide informed consent and follow all study procedures, including attending all scheduled visits.~Exclusion Criteria:~1. Documented hypoglycemia occurring in the fasting state (\> 12 hours fast);~2. Chronic kidney disease stage 4 or 5 (including end-stage renal disease);~3. Hepatic disease, including serum alanine transaminase (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin \< 3.0 g/dL; or serum bilirubin \>2.0;~4. Congestive heart failure, New York Heart Association (NYHA) class II, Ill or IV;~5. History of myocardial infarction, unstable angina or revascularization within the past 6 months or 2 or more risk factors for coronary artery disease including diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, and active tobacco use.~6. History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia~7. Concurrent administration of beta-blocker therapy;~8. History of a cerebrovascular accident;~9. Seizure disorder (other than with suspect or documented hypoglycemia);~10. Active treatment with any diabetes medications except for acarbose;~11. Active treatment with octreotide or diazoxide;~12. Active malignancy, except basal cell or squamous cell skin cancers;~13. Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (multiple endocrine neoplasia (MEN) 2, neurofibromatosis, or Von Hippel-Lindau disease);~14. Known insulinoma;~15. Major surgical operation within 30 days prior to screening;~16. Hematocrit\< 33%;~17. Bleeding disorder, treatment with warfarin, or platelet count \<50,000;~18. Blood donation (1 pint of whole blood) within the past 2 months;~19. Active alcohol abuse or substance abuse;~20. Current administration of oral or parenteral corticosteroids;~21. Pregnancy and/ or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill/patch I vaginal ring, Depo-Provera, Norplant, an intrauterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.~22. Use of an investigational drug within 30 days prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Masked CGM Wear (Phase 1) (Type: OTHER): Each participant will wear the Dexcom CGM for two sequential phases. During the first phase, participants will not be able to read the sensor glucose levels (masked).
- Unmasked CGM Wear (Phase 2) (Type: EXPERIMENTAL): In the second phase, participants will be able to read the sensor glucose levels (unmasked). Frequency of hypoglycemia will be compared between the two phases of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete